Contact the Editorial Desk

Editorial correspondence

Peptide Scienes welcomes correspondence that improves the accuracy or currency of this file: a citation quoted imprecisely, a newly published trial on CJC-1295, GHK-Cu, semaglutide, or tesamorelin, or a regulatory update that changes an approval status described on the references page. This is the category of message a reporting-style file most needs, and each one is read carefully.

The most useful submissions specify the exact page, the exact passage in question, and a supporting source — a DOI or PubMed identifier where possible — so a proposed correction can be checked against its source before anything changes.

Editorial mailbox: editors@peptidescienes.com

What this desk cannot do

So no message goes unanswered for the wrong reason: this is a literature file, not a clinical service, and it cannot advise on or recommend human use of any peptide discussed here, suggest a dose or schedule for any person, judge whether a cited trial's findings apply to someone's specific situation, or help source, sell, or locate any compound from any supplier. It also cannot advise athletes on anti-doping questions, though it is worth noting plainly that CJC-1295 and tesamorelin both fall under the World Anti-Doping Agency's prohibited list.

Semaglutide and tesamorelin are prescription medicines available only through licensed providers. Readers seeking medical guidance should consult a licensed clinician in their own jurisdiction. Responses to editorial correspondence are not guaranteed and may take time; the mailbox is monitored periodically rather than continuously.